Received Jun 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENQUADFI) | SANOFI PASTEUR | UNK | — | — |
Pt was given an extra dose of MenQuadfi instead of Bexero. No adverse effects or reactions observed or noted.Pt was requesting a Meningococcal B vaccine for college. Patient was consulted for the Mengicoccal B vaccine. I highlighted the Mengicoccal B space on the CIS and entered the date after patient received her vaccine in the Meningococcal B space on the CIS. I accidently wrote MenACWY on the consent from and this resulted in the patient receiving the MenACWY. I notified the on-call provider about the patient receiving the extra dose of MenACWY. She advised that the patient would not have any adverse reactions to the extra dose and it would be safe if the patient came back and received the correct Meningococcal B vaccine. The patient was notified via phone call with no answer. The patient was then notified via text and she call me back. She gave verbal understanding about the incident and decided to come back and receive the correct vaccine. Pt did return and received the Meningococcal B vaccine. Pt was monitored and no noted reactions were observed. She received education regarding any adverse and urgent side effects and who to notify in case of an emergency. Pt gave verbal understanding.
none
none
unknown
none
Clinical supervisor was notified. On-call provider was notified, Pt was notified and given education regarding extra dose of vaccine.